Esperion Therapeutics Inc (ESPR) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $3.18 (-0.31%), Market cap $0.81B, 52-week low–high $0.79 ~ $4.08.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-reg
Financial statements, price targets, institutional (13F) holdings and related news for Esperion Therapeutics Inc are updated in real time on BlackAll Trade.
Esperion Therapeutics Inc trades at $3.18 (-0.31%). Real-time quotes and charts are available on BlackAll Trade.
Esperion Therapeutics Inc has a market cap of about $0.81B.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United St